科伦药业：棕榈酸帕利哌酮注射液获批药品注册

Core Viewpoint - Kolun Pharmaceutical's subsidiary, Hunan Kolun Pharmaceutical Co., Ltd., has received drug registration approval from the National Medical Products Administration for its chemical drug "Paliperidone Palmitate Injection," which is used for the treatment of acute and maintenance phases of schizophrenia [1] Group 1 - The approved drug is specifically indicated for the treatment of schizophrenia, addressing both acute and maintenance phases [1] - The approval marks a significant milestone for Kolun Pharmaceutical, enhancing its product portfolio in the psychiatric treatment segment [1]